<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20089540</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of antimicrobial chemotherapy</Title><ISOAbbreviation>J Antimicrob Chemother</ISOAbbreviation></Journal><ArticleTitle>Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid.</ArticleTitle><Pagination><StartPage>676</StartPage><EndPage>683</EndPage><MedlinePgn>676-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkp502</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Enterovirus 71 (EV71) causes serious diseases in humans. The aim of this study was to examine the effects of aurintricarboxylic acid (ATA) on EV71 replication and to explore the underlying mechanism.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To measure the activity of ATA in inhibiting the cytopathic effect (CPE) of EV71, a cell-based neutralization (inhibition of virus-induced CPE) assay was performed. The effect of ATA was further confirmed using plaque reduction and viral yield reduction assays. A time of addition assay was performed to identify the mechanisms of ATA's anti-EV71 activity. We examined the effects of ATA on the following key steps involved in virus replication: (i) translation of the internal ribosomal entry site (IRES)-mediated viral polyprotein; (ii) the proteolytic activity of viral proteases 2A and/or 3C; and (iii) the viral 3D RNA-dependent RNA polymerase (RdRp) activity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In this study, ATA was found to be a potent inhibitor of the replication of EV71. In the antiviral neutralization assay, ATA exhibited inhibitory activity against EV71 (TW/4643/98) and EV71 (TW/2231/98). Plaque assay further demonstrated that ATA inhibited EV71 replication with an EC(50) (effective concentration at which 50% of plaques were removed) of 2.9 microM. Studies on the mechanism of action revealed that ATA targets the early stage of the viral life cycle after viral entry. ATA was able to inhibit the RdRp activity of EV71, while neither the IRES-mediated translation of viral polyprotein nor the viral 3C protease activity was affected.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Overall, the findings in this study suggest that ATA is able to effectively inhibit EV71 replication through interfering with the viral 3D polymerase.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Hui-Chen</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Biological Science and Technology, National Chiao Tung University, Hsin-Chu, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Tzu-Chun</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Ming-Yu</ForeName><Initials>MY</Initials></Author><Author ValidYN="Y"><LastName>Yen</LastName><ForeName>Kuei-Jung</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Shin-Ru</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>John T-A</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Ching-Ping</ForeName><Initials>CP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Antimicrob Chemother</MedlineTA><NlmUniqueID>7513617</NlmUniqueID><ISSNLinking>0305-7453</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>4431-00-9</RegistryNumber><NameOfSubstance UI="D001312">Aurintricarboxylic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber><NameOfSubstance UI="D012324">RNA-Dependent RNA Polymerase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001312" MajorTopicYN="N">Aurintricarboxylic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003588" MajorTopicYN="N">Cytopathogenic Effect, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012324" MajorTopicYN="N">RNA-Dependent RNA Polymerase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010948" MajorTopicYN="N">Viral Plaque Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20089540</ArticleId><ArticleId IdType="pmc">PMC7110181</ArticleId><ArticleId IdType="doi">10.1093/jac/dkp502</ArticleId><ArticleId IdType="pii">dkp502</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pallansch M, Roos R. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Knipe D, Howley P, editors. Fields Virology. 4th edn. Baltimore: Williams and Wilkins; 2001. pp. 840&#x2013;93.</Citation></Reference><Reference><Citation>Shih SR, Ho MS, Lin KH, et al. Genetic analysis of enterovirus 71 isolated from fatal and non-fatal cases of hand, foot and mouth disease during an epidemic in Taiwan, 1998. Virus Res. 2000;68:127&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">10958984</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TC, Weng KF, Chang SC, et al. Development of antiviral agents for enteroviruses. J Antimicrob Chemother. 2008;62:1169&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">18931391</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma AM, Vliegen I, De Clercq E, et al. Selective inhibitors of picornavirus replication. Med Res Rev. 2008;28:823&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">18381747</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbinati C, Chiodelli P, Rusnati M. Polyanionic drugs and viral oncogenesis: a novel approach to control infection, tumor-associated inflammation and angiogenesis. Molecules. 2008;13:2758&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6245429</ArticleId><ArticleId IdType="pubmed">19002078</ArticleId></ArticleIdList></Reference><Reference><Citation>De Clercq E. New developments in anti-HIV chemotherapy. Biochim Biophys Acta. 2002;1587:258&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084468</ArticleId></ArticleIdList></Reference><Reference><Citation>Santhosh KC, Paul GC, De Clercq E, et al. Correlation of anti-HIV activity with anion spacing in a series of cosalane analogues with extended polycarboxylate pharmacophores. J Med Chem. 2001;44:703&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">11262081</ArticleId></ArticleIdList></Reference><Reference><Citation>Witvrouw M, Fikkert V, Pluymers W, et al. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Mol Pharmacol. 2000;58:1100&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11040059</ArticleId></ArticleIdList></Reference><Reference><Citation>Myskiw C, Deschambault Y, Jefferies K, et al. Aurintricarboxylic acid inhibits the early stage of vaccinia virus replication by targeting both cellular and viral factors. J Virol. 2007;81:3027&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865980</ArticleId><ArticleId IdType="pubmed">17192307</ArticleId></ArticleIdList></Reference><Reference><Citation>Geber WF, Lefkowitz SS, Hung CY. Effect of ascorbic acid, sodium salicylate, and caffeine on the serum interferon level in response to viral infection. Pharmacology. 1975;13:228&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">168598</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap Y, Zhang X, Andonov A, et al. Structural analysis of inhibition mechanisms of aurintricarboxylic acid on SARS-CoV polymerase and other proteins. Comput Biol Chem. 2005;29:212&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7106521</ArticleId><ArticleId IdType="pubmed">15979041</ArticleId></ArticleIdList></Reference><Reference><Citation>De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther. 2006;4:291&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105749</ArticleId><ArticleId IdType="pubmed">16597209</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung HC, Tseng CP, Yang JM, et al. Aurintricarboxylic acid inhibits influenza virus neuraminidase. Antiviral Res. 2009;81:123&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7114187</ArticleId><ArticleId IdType="pubmed">19014974</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Bopda-Waffo A, Basu A, et al. Characterization of aurintricarboxylic acid as a potent hepatitis C virus replicase inhibitor. Antivir Chem Chemother. 2009;20:19&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">19794229</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TC, Chang HY, Lin PF, et al. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob Agents Chemother. 2009;53:2740&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2704669</ArticleId><ArticleId IdType="pubmed">19414569</ArticleId></ArticleIdList></Reference><Reference><Citation>Verheyden B, Andries K, Rombaut B. Mode of action of 2-furylmercury chloride, an anti-rhinovirus compound. Antiviral Res. 2004;61:189&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">15168800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JY, Li ML, Shih SR. Far upstream element binding protein 2 interacts with enterovirus 71 internal ribosomal entry site and negatively regulates viral translation. Nucleic Acids Res. 2009;37:47&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615614</ArticleId><ArticleId IdType="pubmed">19010963</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JC, Shih SR, Chang TY, et al. A mammalian cell-based reverse two-hybrid system for functional analysis of 3C viral protease of human enterovirus 71. Anal Biochem. 2008;375:115&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">18190777</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, Tsai KN, Li YS, et al. Inhibition of enterovirus 71-induced apoptosis by allophycocyanin isolated from a blue-green alga Spirulina platensis. J Med Virol. 2003;70:119&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">12629652</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TC, Liu SC, Huang PN, et al. Antiviral activity of pyridyl imidazolidinones against enterovirus 71 variants. J Biomed Sci. 2008;15:291&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">18196474</ArticleId></ArticleIdList></Reference><Reference><Citation>Chern JH, Chang CS, Tai CL, et al. Synthesis and antipicornavirus activity of (R)- and (S)-1-[5-(4&#x2032;-chlorobiphenyl-4-yloxy)-3-methylpentyl]-3-pyridin-4-yl-imidazolidin-2-one. Bioorg Med Chem Lett. 2005;15:4206&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054357</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CS, Lin YT, Shih SR, et al. Design, synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy)alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives. J Med Chem. 2005;48:3522&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15887961</ArticleId></ArticleIdList></Reference><Reference><Citation>Chern JH, Lee CC, Chang CS, et al. Synthesis and antienteroviral activity of a series of novel, oxime ether-containing pyridyl imidazolidinones. Bioorg Med Chem Lett. 2004;14:5051&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15380197</ArticleId></ArticleIdList></Reference><Reference><Citation>Chern JH, Shia KS, Hsu TA, et al. Design, synthesis, and structure&#x2013;activity relationships of pyrazolo[3,4-d]pyrimidines: a novel class of potent enterovirus inhibitors. Bioorg Med Chem Lett. 2004;14:2519&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">15109643</ArticleId></ArticleIdList></Reference><Reference><Citation>Shia KS, Li WT, Chang CM, et al. Design, synthesis, and structure&#x2013;activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors. J Med Chem. 2002;45:1644&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">11931618</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih SR, Tsai MC, Tseng SN, et al. Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob Agents Chemother. 2004;48:3523&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC514779</ArticleId><ArticleId IdType="pubmed">15328120</ArticleId></ArticleIdList></Reference><Reference><Citation>Cory AH, Owen TC, Barltrop JA, et al. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991;3:207&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">1867954</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods. 1988;20:309&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">2460479</ArticleId></ArticleIdList></Reference><Reference><Citation>Castello A, Alvarez E, Carrasco L. Differential cleavage of eIF4GI and eIF4GII in mammalian cells. Effects on translation. J Biol Chem. 2006;281:33206&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">16959778</ArticleId></ArticleIdList></Reference><Reference><Citation>Castello A, Izquierdo JM, Welnowska E, et al. RNA nuclear export is blocked by poliovirus 2A protease and is concomitant with nucleoporin cleavage. J Cell Sci. 2009;122:3799&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">19789179</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew DJ, Hay AW, Evans SW. Aurintricarboxylic acid inhibits apoptosis and supports proliferation in a haemopoietic growth-factor dependent myeloid cell line. Immunopharmacology. 1999;41:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">9950264</ArticleId></ArticleIdList></Reference><Reference><Citation>Benchokroun Y, Couprie J, Larsen AK. Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Biochem Pharmacol. 1995;49:305&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">7857317</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H, Lee DY, Shrestha S, et al. Aurintricarboxylic acid translocates across the plasma membrane, inhibits protein tyrosine phosphatase and prevents apoptosis in PC12 cells. Mol Cells. 2004;18:46&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">15359123</ArticleId></ArticleIdList></Reference><Reference><Citation>De Clercq E. The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures. Med Res Rev. 2009 doi: 10.1002/med.20179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.20179</ArticleId><ArticleId IdType="pmc">PMC7168424</ArticleId><ArticleId IdType="pubmed">19844936</ArticleId></ArticleIdList></Reference><Reference><Citation>Milani M, Mastrangelo E, Bollati M, et al. Flaviviral methyltransferase/RNA interaction: structural basis for enzyme inhibition. Antiviral Res. 2009;83:28&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127253</ArticleId><ArticleId IdType="pubmed">19501254</ArticleId></ArticleIdList></Reference><Reference><Citation>He R, Adonov A, Traykova-Adonova M, et al. Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid. Biochem Biophys Res Commun. 2004;320:1199&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7111066</ArticleId><ArticleId IdType="pubmed">15249217</ArticleId></ArticleIdList></Reference><Reference><Citation>Cushman M, Wang PL, Chang SH, et al. Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weight. J Med Chem. 1991;34:329&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">1704065</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>